Automata, a leader in open, integrated laboratory automation, announces its expansion into the US. Automata is accelerating scientific and health outcomes by making automation a reality for every lab.
The life sciences are leading the most important scientific revolution since computing accounting for approximately 7% of all US economic activity with the global life sciences tools market alone estimated at $102B in 2021. Alongside generating a step change in health outcomes due to innovations in diagnostic and therapeutic modalities. This is happening in pharma, biotechs, CROs, CDMOs, hospitals and diagnostic organizations. These organizations all have labs at their core which are extremely inefficient, manually intensive and facing fundamental challenges to scale.
Also Read: Consumer Biotech Company Tally Health Launches Platform Aimed at Extending Longevity
Automata’s mission is to unlock labs’ space, people, and potential through automation hardware and software that accelerate workflows in pharmaceutical and biotech companies, academic institutes, core testing labs and contract development and manufacturing. Automata enters this market at an exciting and critical time, as the US is considered the global leader in Life Sciences with more than a third of all life sciences companies headquartered in the country.With Automata’s technology, the US life sciences industry will be empowered to cut workflow times by up to 50%, increase output, maximize existing lab space, and free up scientists to work on innovative research.
Their expansion comes following successful growth and customer partnerships in the UK since the company’s launch, including raising $50m in Series B funding in 2022. Its partnerships in the UK include supporting bit.bio to scale the manufacturing of human cells; powering genome sample preparation at The Francis Crick Institute; and automating diagnostic testing with the UK’s National Health Service (NHS).
Mostafa ElSayed, Co-Founder and CEO of Automata, explained: “The lab of the future is an automated one, where scientists have the capacity to work on innovative research, while automated systems effectively and efficiently carry out routine tasks.
SOURCE: Businesswire